GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator

- Regulatory submission included data from pivotal trials addressing key clinical manifestations of myelofibrosis, namely splenomegaly, constitutional symptoms and anaemia

GSK plc (LSE/NYSE: GSK) today announced that the Ministry of Health, Labour and Welfare (MHLW), Japan, has accepted for review a new drug application (NDA) for momelotinib, a potential new medicine with a differentiated mechanism of action that may address the significant medical needs of myelofibrosis patients, especially those with anaemia. The NDA is based on data from the pivotal phase III trials SIMPLIFY-1 and MOMENTUM.

Myelofibrosis is a blood cancer that can lead to splenomegaly (enlarged spleen); constitutional symptoms such as fatigue, night sweats, and bone pain; and severely low blood counts, including anaemia and thrombocytopenia. About 70% of patients diagnosed with primary myelofibrosis and about half of patients diagnosed with secondary myelofibrosis in Japan have moderate to severe anaemia at the time of diagnosis, and nearly all patients are estimated to develop anaemia over the course of the disease. Patients who are transfusion dependent have a poor prognosis and shortened survival.

Momelotinib is not currently approved in any market.

About momelotinib
Momelotinib has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1). Inhibition of JAK1 and JAK2 may improve constitutional symptoms and splenomegaly. Additionally, inhibition of ACVR1 leads to a decrease in circulating hepcidin, which is elevated in myelofibrosis and contributes to anaemia.

About myelofibrosis
Myelofibrosis is a rare blood cancer that disrupts the body’s normal production of blood cells as a result of dysregulated JAK-signal transducer and activator of transcription protein signalling. The clinical hallmarks of myelofibrosis are progressive splenomegaly (enlarged spleen), anaemia and debilitating symptoms attributable to ineffective hematopoiesis and excessive production of proinflammatory cytokines. Myelofibrosis patients with anaemia require additional supportive care, including transfusions, and have poor outcomes. Myelofibrosis affects approximately 1 in 500,000 people worldwide, with up to 5,000 patients impacted in Japan.

About the pivotal SIMPLIFY-1 clinical trial
SIMPLIFY-1 was a multicentre randomised, double-blind, phase III study that compared the safety and efficacy of momelotinib to ruxolitinib in patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. SIMPLIFY-1 met its primary endpoint, demonstrating non-inferiority of momelotinib to ruxolitinib in spleen volume response (reduction by 35% or greater), and substantial improvements in transfusion independence rates.

About the pivotal MOMENTUM clinical trial
MOMENTUM was a global, randomised, double-blind phase III clinical trial of momelotinib (MMB) versus danazol (DAN) in patients with myelofibrosis who were symptomatic and anaemic and had been previously treated with an approved JAK inhibitor. The MOMENTUM trial met all its primary and key secondary endpoints, with respect to splenic response, constitutional symptoms and transfusion independence. Results from the 24-week treatment
Stock-exchange announcement
For media and investors only

period were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and subsequently published in *The Lancet*.⁴

GSK in oncology
GSK is committed to maximising patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumour-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers and other solid tumours.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK enquires

<table>
<thead>
<tr>
<th>Media:</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Foley</td>
<td>+44 (0) 20 8047 5502 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarah Clements</td>
<td>+44 (0) 20 8047 5502 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathleen Quinn</td>
<td>+1 202 603 5003 (Washington DC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyndsay Meyer</td>
<td>+1 202 302 4595 (Washington DC)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investor Relations:</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Stone</td>
<td>+44 (0) 7717 618834 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>James Dodwell</td>
<td>+44 (0) 20 8047 2406 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mick Readey</td>
<td>+44 (0) 7990 339653 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Josh Williams</td>
<td>+44 (0) 7385 415719 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Camilla Campbell</td>
<td>+44 (0) 7803 050238 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steph Mountifield</td>
<td>+44 (0) 7796 707505 (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeff McLaughlin</td>
<td>+1 215 751 7002 (Philadelphia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frannie DeFranco</td>
<td>+1 215 751 4855 (Philadelphia)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in the company’s Annual Report on Form 20-F for 2022, and Q2 Results for 2023 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

---


Stock-exchange announcement

For media and investors only

---